Hemoglobin Oxygen Therapeutics, which is relaunching hemoglobin-based oxygen carriers for human and veterinary use, filed on Tuesday with the SEC to raise up to $30 million in an initial public offering.
The company is focused on the development, manufacture, and commercialization of hemoglobin-based oxygen carries (HBOCs) for use in both human and veterinary medicine. Its current products are Hemopure for human use and Oxyglobin for veterinary use, which are are sterile medicinal products administered via intravenous or arterial infusion that deliver oxygen to organs and tissues that could provide a potential alternative to blood transfusion. Hemopure and Oxyglobin were acquired from OPK Biotech in 2014, which had previously purchase them from Biopure in 2009. Hemoglobin Oxygen Therapeutics’ immediate focus is to relaunch Hemopure and Oxyglobin under approved indications in jurisdictions where they already have marketing authorizations.
The Souderton, PA-based company traces its roots to 1984 and plans to list on the Nasdaq under the symbol HOTI. WestPark Capital is the sole bookrunner on the deal. No pricing terms were disclosed.
